ArticleBMC cardiovascular disorders2025
The methylation of TXNRD2 with chronic heart failure: the interaction effect between methylation regulation and clinical parameters-- a single center pilot study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study investigated the potential role of TXNRD2_FA44 promoter methylation in chronic heart failure (CHF) and its influence on disease mechanisms. Additionally, we explored the association between specific Cytosine-phosphate-Guanine (CpG) site methylation levels within the TXNRD2_FA44 promoter and various biochemical markers in CHF patients.
methodsThe study included 20 individuals suffering from chronic heart failure and an equal number of healthy participants. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF–MS), CpG sites in the TXNRD2_FA44 promoter region were pinpointed and measured. The comparison of methylation levels was conducted between CHF patients and healthy individuals. Statistics was used to analyze the relationship between TXNRD2_FA44_CpG_27.28.29 and various key biochemical indicators.
resultsPatients with CHF exhibited significantly higher methylation levels at TXNRD2_FA44_CpG_27.28.29 compared to controls (P = 0.0008). This elevated methylation level correlated with levels of creatinine (Crea), estimated glomerular filtration rate (eGFR), percentage of lymphocytes (LYMPH), albumin (ALB), globulin (GLB), and the albumin-to-globin ratio (A/G) in CHF patients.
conclusionsThe methylation level of TXNRD2-FA44 in patients with chronic heart failure is significantly higher than controls, and the methylation level of TXNRD2-FA44 is related to multiple liver and kidney function indicators. These findings suggest that TXNRD2-FA44 could serve as a biomarker for CHF diagnosis and may affect the occurrence and development of CHF through liver and kidney function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.